샤페론

378800KOSDAQ기초 의약물질 제조업

45.3 / 100

Reference Date: 2026-04-13

Financial Score16.5 / 40

News Sentiment13.8 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Slightly up 1.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Shapieron is a biotech venture specializing in drug development, leveraging its platform targeting GPCR19 to inhibit inflammatory complexes. The company is conducting clinical trials for COVID-19 and Alzheimer's treatments, while expanding into ADC and RPT-based nanobody development. It has established a U.S. subsidiary and demonstrated commercialization capabilities through two technology transfers.

Number of Employees

53people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 33.454.0Point

PBR

3.29Industry Average 2.031.0Point

1.6x industry avg (risky)

ROE

-76.22Industry Average -4.293.5Point

17.8x industry avg (excellent)

Debt Ratio

4.65Industry Average 6.615.0Point

Lower than industry avg (good)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲547.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼9.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -70.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 1Neutral 0Negative 0Average Sentiment Score 70

Positive
샤페론, 바이오 유럽 스프링 참가…'누겔' 사업화 논의
샤페론은 글로벌 바이오 파트너링 행사 '바이오 유럽 스프링 2026'에 참가하여 19개 글로벌 제약·바이오 기업과 핵심 파이프라인 '누겔'의 사업화 전략을 논의합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 1,758Won52-week high 3,33852-week low 1,606

1-month return3.0Point

1m 1.03% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral주요사항보고서(전환사채권발행결정)2026-04-07
Neutral정기주주총회결과2026-03-27
Neutral감사보고서제출2026-03-19
Neutral사업보고서 (2025.12)2026-03-19